Antag Therapeutics is a Copenhagen-based preclinical stage biotechnology company focused on developing therapies for dietary-related metabolic diseases. The company’s current lead therapy is a glucose-dependent insulinotropic peptide receptor (GIPR) antagonist for inducing weight loss in obese patients with Type-2 Diabetes. The Company’s technology is based upon decades of incretin physiology and diabetes research from the laboratories of Professors Mette Rosenkilde and Jens Juul Holst at the University of Copenhagen, which played a pivotal role

in the establishment of dipeptidyl peptidase 4 (DPP-4) inhibitor and glucagon-like peptide-1 (GLP-1) agonist drug classes.

https://www.antagtherapeutics.com